177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

February 28, 2035

Conditions
Adenoid Cystic Carcinoma
Interventions
DRUG

177Lu-PNT2002

"10 patients will undergo DCFPyL PET/CT and 177Lu-PSMA dosimetry imaging only (single tracer dose).~If opened, Cohort 2 patients will receive 4 cycles, every 8 weeks of 177Lu-PSMA infusion. Other procedures during treatment and follow up may include: physical exam, CT/MRI, PSMA-PET, blood draws, adverse event assessment, and completion of questionnaires."

Trial Locations (1)

21287

RECRUITING

Johns Hopkins Hospital, Baltimore

All Listed Sponsors
collaborator

Adenoid Cystic Carcinoma Research Foundation

OTHER

collaborator

Progenics Pharmaceuticals, Inc.

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER